Reading the results of the ALKS3831 study. Wondering about using a mu opioid antagonist with Zyprexa. Is this going to cause dysphoria in patient already suffering from schizophrenia? Believe the FDA will require extensive testing and the outcome seems to me to be uncertain whether it can win approval. Any ideas? Long ALKS questioning ALKS3831.
The mu receptor is not implcated in the pathology schizophrenia. Further, partial or full blockade of the mu recptor does not mute hedonic response. Other receptors, i.e., kappa are also responsible for releasing dopamine.
Thanks for your knowledgeable reply. I feel better about the project, but I still believe that that the FDA will require studies to show that ALKS33 does not worsen the outcome for schizophrenic patients. These are expensive trials. I hope it is worth it.